Stockscreener 앱 받기
55.80
0.53%
-0.27
전일 마감가:
$56.07
열려 있는:
$56
하루 거래량:
79,526
Relative Volume:
0.12
시가총액:
$5.20B
수익:
$4.72M
순이익/손실:
$-258.54M
주가수익비율:
-16.36
EPS:
-3.41
순현금흐름:
$-185.05M
1주 성능:
-6.52%
1개월 성능:
-4.99%
6개월 성능:
+12.67%
1년 성능:
+86.28%
1일 변동 폭
$55.30
$56.65
1주일 범위
$52.84
$60.15
52주 변동 폭
$29.72
$62.53
Crinetics Pharmaceuticals Inc Stock (CRNX) Company Profile
명칭
Crinetics Pharmaceuticals Inc
전화
858-450-6464
주소
10222 BARNES CANYON ROAD, BLDG. #2, SAN DIEGO, CA
CRNX을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
| CRNX | 55.75 | 5.20B | 4.72M | -258.54M | -185.05M | -3.41 |
| VRTX | 446.48 | 115.74B | 10.63B | -479.80M | -1.35B | 13.33 |
| REGN | 740.49 | 81.65B | 13.85B | 4.65B | 3.32B | 35.06 |
| ARGX | 591.15 | 34.86B | 1.86B | -40.29M | -1.28B | -4.16 |
| ALNY | 249.56 | 32.09B | 2.09B | -332.26M | 16.06M | -4.14 |
| BNTX | 103.47 | 24.49B | 3.30B | -501.07M | 1.03B | 11.54 |
Crinetics Pharmaceuticals Inc Stock (CRNX) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2024-03-06 | 개시 | Citigroup | Buy |
| 2024-01-16 | 개시 | Morgan Stanley | Overweight |
| 2023-12-21 | 개시 | Jefferies | Hold |
| 2023-11-20 | 재개 | JP Morgan | Overweight |
| 2023-10-24 | 재개 | Cantor Fitzgerald | Overweight |
| 2023-08-31 | 개시 | Oppenheimer | Outperform |
| 2023-04-24 | 개시 | Piper Sandler | Overweight |
| 2023-03-30 | 개시 | Robert W. Baird | Outperform |
| 2021-11-30 | 개시 | JMP Securities | Mkt Outperform |
| 2021-11-23 | 개시 | Evercore ISI | Outperform |
| 2021-06-18 | 업그레이드 | JP Morgan | Neutral → Overweight |
| 2019-12-23 | 개시 | ROTH Capital | Buy |
| 2019-02-14 | 개시 | H.C. Wainwright | Buy |
| 2018-08-13 | 개시 | JP Morgan | Neutral |
| 2018-08-13 | 개시 | Leerink Partners | Outperform |
| 2018-08-13 | 개시 | Piper Jaffray | Overweight |
모두보기
Crinetics Pharmaceuticals Inc 주식(CRNX)의 최신 뉴스
Jennison Associates LLC Acquires 13,470 Shares of Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) - MarketBeat
Victory Capital Management Inc. Purchases 116,657 Shares of Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) - MarketBeat
First Turn Management LLC Cuts Holdings in Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) - MarketBeat
Leerink Partnrs Issues Optimistic Forecast for CRNX Earnings - MarketBeat
Learn to Evaluate (CRNX) using the Charts - Stock Traders Daily
FY2024 Earnings Forecast for CRNX Issued By Lifesci Capital - Defense World
HC Wainwright Has Bearish Estimate for CRNX FY2024 Earnings - Defense World
Steven Cohen's Recent Transaction in Crinetics Pharmaceuticals Inc - GuruFocus.com
Crinetics Pharmaceuticals : 2024 Citi Global Healthcare Conference - Marketscreener.com
Crinetics Pharmaceuticals : Piper Sandler 36th Annual Healthcare Conference - Marketscreener.com
Crinetics Pharmaceuticals : 2024 Evercore 7th Annual HealthCONx Conference - Marketscreener.com
Crinetics Pharmaceuticals : 2024 Cantor Global Healthcare Conference - Marketscreener.com
Crinetics Pharmaceuticals to Participate in Three Upcoming December Investor Conferences - The Manila Times
Crinetics Pharmaceuticals to Present at Three Major Healthcare Investor Conferences | CRNX Stock News - StockTitan
EcoR1 Capital, LLC Increases Stake in Crinetics Pharmaceuticals Inc - GuruFocus.com
HC Wainwright Has Pessimistic View of CRNX FY2024 Earnings - MarketBeat
Crinetics Pharmaceuticals (NASDAQ:CRNX) Sets New 52-Week High Following Analyst Upgrade - Defense World
UPDATE: Crinetics Pharmaceuticals to Showcase Pipeline - GlobeNewswire
UPDATE: Crinetics Pharmaceuticals to Showcase Pipeline Advancements with Neuroendocrine Tumor Candidates at The North American Neuroendocrine Tumor Society (NANETS) Annual Meeting - The Manila Times
Crinetics Unveils Breakthrough Cancer Drug Platform, Reports Positive Phase 2 Trial Results | CRNX Stock News - StockTitan
Crinetics Pharmaceuticals Third Quarter 2024 Earnings: US$0.96 loss per share (vs US$1.01 loss in 3Q 2023) - Yahoo Finance
Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) Receives Consensus Rating of "Moderate Buy" from Analysts - MarketBeat
Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) Given Consensus Rating of “Moderate Buy” by Analysts - Defense World
Crinetics Pharmaceuticals (NASDAQ:CRNX) Posts Quarterly Earnings Results, Misses Expectations By $0.05 EPS - MarketBeat
Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) Q3 2024 Earnings Call Transcript - Insider Monkey
Crinetics Pharmaceuticals Inc (CRNX) Q3 2024 Earnings Call Highl - GuruFocus.com
Crinetics Pharmaceuticals Inc (CRNX) Q3 2024 Earnings Call Highlights: Strategic Advances and ... - Yahoo Finance
Acromegaly Market Forecasted to Surge in Coming Years, 2024-2034 Analysis by DelveInsight | Amryt Pharma, Chiasma, Recordati, Novartis, Crinetics Pharma, Camurus AB, Ionis Pharma - The Globe and Mail
Crinetics Pharmaceuticals Reports Third Quarter 2024 Financial Results and Provides Business Update - GlobeNewswire
Crinetics Pharmaceuticals, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
Crinetics Pharmaceuticals to Showcase Pipeline Advancements - GlobeNewswire
Crinetics Pharmaceuticals, Inc. Announces Additional Data from the 2 Study of Its Investigational Drug Atumelnant in Cah Is Anticipated by Early 2025 - Marketscreener.com
Crinetics' Breakthrough: Phase 2 Trial Success & Novel NET Treatment Pipeline Advances | CRNX Stock News - StockTitan
Crinetics Pharma Raises $575M, Advances Acromegaly Drug as Cash Runway Extends to 2029 | CRNX Stock News - StockTitan
Acromegaly Market Forecasted to Surge in Coming Years, - openPR
CRNXCrinetics Pharmaceuticals, Inc. Latest Stock News & Market Updates - StockTitan
Crinetics Pharmaceuticals Announces November 2024 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Crinetics Grants 99,500 Stock Options to New Hires at $60.69, Expanding Team | CRNX Stock News - StockTitan
Lisanti Capital Growth LLC Increases Stock Position in Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) - MarketBeat
Crinetics Pharmaceuticals (CRNX) to Release Earnings on Tuesday - Defense World
Fiera Capital Corp Sells 14,334 Shares of Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) - MarketBeat
Wellington Management Group LLP Reduces Stake in Crinetics Pharm - GuruFocus.com
CRNX (Crinetics Pharmaceuticals) Total Inventories : $0.00 Mil (As of Jun. 2024) - GuruFocus.com
(CRNX) Technical Pivots with Risk Controls - Stock Traders Daily
Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) Shares Sold by abrdn plc - MarketBeat
Vanguard Group Inc's Strategic Acquisition in Crinetics Pharmace - GuruFocus.com
Acromegaly Pipeline 2024: Clinical Trials Assessment, FDA - openPR
Investors might be losing patience for Crinetics Pharmaceuticals' (NASDAQ:CRNX) increasing losses, as stock sheds 5.6% over the past week - Yahoo Finance
Moody Aldrich Partners LLC Sells 11,053 Shares of Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) - MarketBeat
Crinetics Pharmaceuticals (NASDAQ:CRNX) Hits New 1-Year HighHere's What Happened - MarketBeat
Analysts Set Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) Target Price at $68.55 - MarketBeat
Crinetics Pharmaceuticals Inc (CRNX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Crinetics Pharmaceuticals Inc 주식 (CRNX) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Pizzuti Dana | Chief Med and Dev Officer |
Oct 03 '24 |
Sale |
54.63 |
14,375 |
785,306 |
28,507 |
0.42%
0.16%
자본화:
|
볼륨(24시간):